Claims for Patent: 9,271,928

Summary for Patent: 9,271,928

Title:	Drug delivery composition
Abstract:	There is provided a non-water soluble drug delivery composition comprising a conjugate and a polymer matrix wherein exposure of the composition to electromagnetic radiation at a suitable pre-determined wavelength and intensity induces release of the active ingredient from the composition. The conjugate is attached to the polymer matrix through non-covalent interactions. There is also provided a drug delivery apparatus formed from the drug delivery composition.
Inventor(s):	McCoy; Colin Peter (South Belfast, GB), Gorman; Sean Patrick (Downpatrick, GB), Jones; David Simon (Newtonabbey, GB)
Assignee:	THE QUEEN\'S UNIVERSITY OF BELFAST (Belfast, GB)
Application Number:	12/996,041
Patent Claims:	1. A non-water soluble drug delivery composition comprising: a conjugate and a polymer matrix said conjugate comprising an active ingredient R bonded to a protecting group via a first functional group; wherein exposure of the composition to electromagnetic radiation at a suitable predetermined wavelength and intensity induces release of the active ingredient from the composition; and wherein the protecting group is selected from the group consisting of: ##STR00007## 2. A non-water soluble drug delivery composition comprising: an active ingredient R; a protecting group; and a polymer matrix, wherein the active ingredient is conjugated to the protecting group; wherein exposure of the composition to electromagnetic radiation at a suitable predetermined wavelength and intensity induces release of the active ingredient from the composition; wherein the polymer matrix is formed from one or more copolymer compounds; wherein the one or more of the copolymer compounds comprises the protecting group; wherein the protecting group is covalently bonded to the one or more copolymer compounds; and wherein the protecting group is selected from the group consisting of ##STR00008## 3. The composition as claimed in claim 1, wherein the active ingredient is bonded to the protecting group via an ester and wherein upon said exposure to electromagnetic radiation the ester group reacts to form a carboxylic acid group on the active ingredient. 4. The composition as claimed in claim 1, wherein the polymer matrix does not comprise cyclodextrin. 5. The composition as claimed in claim 1, dissolving 5 parts per million or less in water. 6. The composition as claimed in claim 1, wherein non-covalent interactions comprise at least one of hydrogen bonds, Van der Waals attractions, .pi.-.pi. interactions, electrostatic interactions or combinations thereof. 7. The composition as claimed in claim 1, wherein the polymer matrix comprises one or more of, poly(ethylene), poly(propylene), polyvinyl chloride), polyvinyl pyrrolidoone), poly(2-hydroxyethyl methacrylate), poly(methyl methacrylate), poly(methacrylic acid), poly(acrylic acid), poly(diethylaminoethylmethacrylate), poly(diethylaminoethylethacrylate), silicone, styrene-isoprene/butadiene-styrene, poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), poly(caprolactone), poly(orthoesters) and; polyphosphazines. 8. The composition as claimed in claim 1 in the form of a tablet, capsule, suspension, cream, ointment, lotion, powder, gel, solution, paste, spray, foam, oil, enema, suppository, controlled or slow release matrix or depot. 9. The composition as claimed in claim 1, wherein the active ingredient is an antibiotic, analgesic, vitamin, anti-histamine, antimicrobial, an anti-histamine, an antipyretic, a hormone, a neurotransmitter or a non-steroidal anti-inflammatory. 10. The composition as claimed in claim 9, wherein the active ingredient is acetyl salicyl, ibuprofen, ketoprofen, gentamicin, ciprofloxacin, diclofenac, nalidixic acid, ofloxacin, ciprofloxacin, erythromycin, clarithromycin, vancomycin, fexofenadine, desloratidine, levocetirizine, olopatadine, levocabastine, gamma-amino butyric acid, lidocaine, amethocaine, testosterone, cholesterol or oestrogen. 11. The composition as claimed in claim 1, wherein the protecting group is substantially permanently incorporated into the polymer matrix and substantially all of the protecting group is retained in the composition throughout and following the exposure of the composition to electromagnetic radiation. 12. The composition as claimed in claim 2, wherein one or more of the copolymer compounds comprises vinyl or acrylate monomers or combinations thereof. 13. A drug delivery apparatus comprising the composition as claimed in claim 1. 14. The drug delivery apparatus of claim 13 in the form of: apheresis equipment, blood bags; blood administration tubing; extracorporeal membrane oxygenation equipment; dialysis and peritoneal drainage bags; urinary collection bags; urological catheters; wound drainage bags and tubes; enteral feeding equipment; nasogastric tubes; breast pump tubes; intravenous catheters, drip chambers, tubing and solution bags; total parenteral nutrition bags; hemodialysis tubing and catheters; film wrap; gloves; endotracheal tubes; tracheostomy tubes; esophageal tubes; humidifiers; ocular prosthesis; or sterile water bags and tubing. 15. The drug delivery apparatus as claimed in claim 13, wherein the apparatus is formed from a material comprising the composition as claimed in claim 1. 16. The drug delivery apparatus of claim 13, wherein the apparatus is formed from a material consisting essentially of the composition as claimed in claim 1. 17. The drug delivery apparatus as claimed in claim 13, comprising a coating of the composition as claimed in claim 1. 18. A method of administering an active ingredient to a patient in need thereof comprising the steps of administering the drug delivery apparatus as claimed in claim 13 to the patient, and exposing the drug delivery apparatus to electromagnetic radiation at a predetermined wavelength and intensity suitable to induce release of the active ingredient from the drug delivery apparatus. 19. The method as claimed in claim 18, wherein the structure and integrity of the polymer matrix is maintained throughout exposure of the drug delivery apparatus to electromagnetic radiation. 20. The method as claimed in claim 18, wherein the rate of release of the active ingredient is predicatable and controllable. 21. The method as claimed in claim 18, wherein the rate of release of the active ingredient is controlled through controlling the wavelength, amplitude and intensity of the electromagnetic radiation or the location and duration of the exposure to electromagnetic radiation. 22. The method as claimed in claim 18, wherein the rate of release of the active ingredient is substantially constant. 23. The method as claimed in claim 18, wherein the release of the active ingredient is stopped and started repeatedly through stopping and starting exposure of the drug delivery apparatus to electromagnetic radiation. 24. The method as claimed in claim 18, wherein at least 99% of the protecting group is retained in the drug delivery apparatus throughout the exposure of the drug delivery apparatus to electromagnetic radiation. 25. The method as claimed in claim 24, wherein at least 99.95% of the protecting group is retained in the drug delivery apparatus throughout the exposure of the drug delivery apparatus to electromagnetic radiation. 26. A method of treating a patient in need thereof comprising the steps of administering the drug delivery apparatus as claimed in claim 13 to the patient and exposing the drug delivery apparatus to electromagnetic radiation at a predetermined wavelength and intensity suitable to induce release of the active ingredient from the drug delivery apparatus. 27. The method as claimed in claim 26, wherein the method is for the treatment of the following diseases or conditions: urinary tract infection, pneumonia, ocular and skin infection, hypersensitivity, glaucoma, posterior capsular opacification, diabetes, epilepsy and pain. 28. The drug delivery apparatus as claimed in claim 13 for use in the treatment of the following diseases or conditions: urinary tract infection, pneumonia, ocular and skin infection, hypersensitivity, glaucoma, posterior capsular opacification, diabetes, epilepsy and pain. 29. The method of forming a drug delivery device as claimed in claim 13, comprising incorporating the composition as claimed in claim 1 in an apparatus suitable for drug delivery. 30. The method as claimed in claim 29, wherein the apparatus suitable for drug delivery is formed from a material and the composition is incorporated into the material prior to formation of the drug delivery apparatus. 31. The method as claimed in claim 29, wherein the composition is coated onto at least a portion of a surface of the apparatus suitable for drug delivery.

Details for Patent 9,271,928

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2028-06-06
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2028-06-06